Lucid Diagnostics (LUCD) Shares Outstanding (2020 - 2026)

Lucid Diagnostics (LUCD) has 7 years of Shares Outstanding (Entity) data on file, last reported at $164.9 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 139.66% year-over-year to $164.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.9 million (up 139.66% YoY) and the FY2025 annual result came in at $101.9 million, up 101.81% from the prior year.
• Shares Outstanding (Entity) climbed to $164.9 million in Q1 2026, from $101.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $164.9 million in Q1 2026 to a low of $35.2 million in Q1 2022.
• A 5-year average of $62.4 million and a median of $46.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 162.25% — and 2023, when it gained 4.47%.
• Tracing LUCD's Shares Outstanding (Entity) over 5 years: stood at $40.5 million in 2022, then grew by 4.47% to $42.3 million in 2023, then increased by 19.34% to $50.5 million in 2024, then surged by 101.81% to $101.9 million in 2025, then jumped by 61.73% to $164.9 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $164.9 million (Q1 2026), $101.9 million (Q4 2025), and $108.2 million (Q3 2025), per Business Quant data.